Community Portal

A place for Clinicians and Healthcare Suppliers to share knowledge and learn more about THE CLINICIAN EXCHANGE



Provided by: Medscape

Real-World Data on Left Atrial Appendage Closure Does Not Reassure

Published: Mon, 26 Jun 2017 09:47:20 EDT
Registry data from EHRA EUROPACE-CARDISTIM 2017 raise concerns that device complications and the need for antithrombotic therapy may limit any potential benefit for left atrial appendage closure. on Medscape

Blink Health Launches Free Type 2 Diabetes Drug Program in US

Published: Mon, 26 Jun 2017 09:44:58 EDT
A large drug-savings platform in the US launches program to give generic antidiabetic drugs away for free for a full year.
Medscape Medical News

Managing the Unique Challenges of Opioids in Cancer Care

Published: Mon, 26 Jun 2017 09:24:51 EDT
Pain management is complex for cancer patients and survivors. Clinicians should expect to see more survivors who need help managing their cancer pain as treatments continue extending survival.
Medscape Oncology

Joseph Mikhael: ASCO 2017 Takeaways in Myeloma

Published: Mon, 26 Jun 2017 09:16:29 EDT
Myeloma expert Joseph Mikhael discusses the studies at ASCO 2017 that affected his practice.
Medscape Oncology
Displaying results 1-4 (of 20)
 1 - 2 - 3 - 4 - 5 


Neothetics decimated by submental fat failure test

Published: Mon, 26 Jun 2017 13:14:04 +0000
It was a short and bitter update out of San Diego’s Neothetics today after it said a phase 2 proof of concept study for its fat reduction therapy flopped.

Matinas BioPharma slumps on phase 2 flop despite positive PR

Published: Mon, 26 Jun 2017 12:42:01 +0000
Small cap biotech Matinas BioPharma was off by nearly 50% premarket on data coming out of its midstage vulvovaginal candidiasis candidate.

Langer’s Kala files for $86M IPO to bring eye drug to market

Published: Mon, 26 Jun 2017 10:44:57 +0000
Kala Pharmaceuticals has filed to list on Nasdaq. The ophthalmic drug R&D shop has penciled in a fundraising goal of $86 million to equip itself to file for approvals of corticosteroid nanosuspension KPI-121 in two indications.

Roche’s emicizumab cuts bleed rate by 87% in hemophilia A

Published: Mon, 26 Jun 2017 09:42:55 +0000
Roche has released a closer look at the data it hopes will propel hemophilia A drug emicizumab to blockbuster status. Emicizumab cut the bleed rate by 87% in patients with inhibitors to factor VIII and aced all the secondary endpoints, leaving lingering concerns about side effects as the main barrier between Roche and big sales.
Displaying results 1-4 (of 25)
 1 - 2 - 3 - 4 - 5 - 6 - 7 

Clinician Owned and Veteran Owned

copyright 2017 THE CLINICIAN EXCHANGE. Privacy Policy